For research use only. Not for therapeutic Use.
3,4-Dehydro Cilostazol (OPC-13015) is an active metabolite of Cilostazol (CLZ; HY-17464). 3,4-Dehydro Cilostazol is used for pharmacokinetic study[1].
3,4-Dehydro Cilostazol (OPC-13015; Oral; 1 mg/kg GLZ and 10 mg/kg CLZ) has a T1/2 of 3.94 hours, a Cmax of 1.39 μM and an AUC0-24 of 4.69 μg•h/ml. The plasma concentration time profiles of GLZ, CLZ & its active metabolite DCLZ are traceable up to 24 h, 12 h and 12 h respectively by oral administration at 1 mg/kg dose of GLZ and 10 mg/kg CLZ[1].
Catalog Number | R006499 |
CAS Number | 73963-62-9 |
Synonyms | 6-[4-(1-cyclohexyltetrazol-5-yl)butoxy]-1H-quinolin-2-one |
Molecular Formula | C20H25N5O2 |
Purity | ≥95% |
InChI | InChI=1S/C20H25N5O2/c26-20-12-9-15-14-17(10-11-18(15)21-20)27-13-5-4-8-19-22-23-24-25(19)16-6-2-1-3-7-16/h9-12,14,16H,1-8,13H2,(H,21,26) |
InChIKey | GHALECSGOJQOHW-UHFFFAOYSA-N |
SMILES | C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)C=C4 |
Reference | [1]. T R S Satheeshmanikandan, et al. Liquid Chromatography – Tandem Mass Spectrometry for the Simultaneous Quantitation of Glipizide, Cilostazol and Its Active Metabolite 3, 4-dehydro-cilostazol in Rat Plasma: Application for a Pharmacokinetic Study. Arzneimi |